Meeting
2019 ASCO Annual Meeting
Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy.
Authors
Chia-Jung Busch
Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
Chia-Jung Busch , Adrian Muenscher , Christian Stephan Betz , Volkan Dogan , Philippe Schafhausen , Carsten Bokemeyer , Mascha Binder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03700905
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS6095)
DOI
10.1200/JCO.2019.37.15_suppl.TPS6095
Abstract #
TPS6095
Poster Bd #
81a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
First Author: Robert L. Ferris
Poster
2021 ASCO Annual Meeting
Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.
First Author: Glenn J. Hanna
Poster
2017 ASCO Annual Meeting
Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.
First Author: Patrick M. Forde
Poster
2023 ASCO Annual Meeting
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).
First Author: Patrick M. Forde